Skip to main content
Springer Nature Link
Log in

Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction

  • Original Paper
  • Published:
Acta Neuropathologica Aims and scope Submit manuscript

Abstract

The two current major staging systems in use for Lewy body disorders fail to classify up to 50% of subjects. Both systems do not allow for large numbers of subjects who have Lewy-type α-synucleinopathy (LTS) confined to the olfactory bulb or who pass through a limbic-predominant pathway that at least initially bypasses the brainstem. The results of the current study, based on examination of a standard set of ten brain regions from 417 subjects stained immunohistochemically for α-synuclein, suggest a new staging system that, in this study, allows for the classification of all subjects with Lewy body disorders. The autopsied subjects included elderly subjects with Parkinson’s disease, dementia with Lewy bodies, incidental Lewy body disease and Alzheimer’s disease with Lewy bodies, as well as comparison groups without Lewy bodies. All subjects were classifiable into one of the following stages: I. Olfactory Bulb Only; IIa Brainstem Predominant; IIb Limbic Predominant; III Brainstem and Limbic; IV Neocortical. Progression of subjects through these stages was accompanied by a generally stepwise worsening in terms of striatal tyrosine hydroxylase concentration, substantia nigra pigmented neuron loss score, Mini Mental State Examination score and score on the Unified Parkinson’s Disease Rating Scale Part 3. Additionally, there were significant correlations between these measures and LTS density scores. It is suggested that the proposed staging system would improve on its predecessors by allowing classification of a much greater proportion of cases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11

Similar content being viewed by others

References

  1. Adler CH (2005) Nonmotor complications in Parkinson’s disease. Mov Disord 20(Suppl 11):S23–S29. doi:10.1002/mds.20460

    Article  PubMed  Google Scholar 

  2. Alafuzoff I, Parkkinen L, Al-Sarraj S, Arzberger T, Bell J, Bodi I, Bogdanovic N, Budka H, Ferrer I, Gelpi E, Gentleman S, Giaccone G, Kamphorst W, King A, Korkolopoulou P, Kovacs GG, Larionov S, Meyronet D, Monoranu C, Morris J, Parchi P, Patsouris E, Roggendorf W, Seilhean D, Streichenberger N, Thal DR, Kretzschmar H (2008) Assessment of alpha-synuclein pathology: a study of the BrainNet Europe Consortium. J Neuropathol Exp Neurol 67:125–143. doi:10.1097/nen.0b013e3181633526

    Article  PubMed  Google Scholar 

  3. Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, Trojanowski JQ, Iwatsubo T (1998) Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson’s disease and dementia with Lewy bodies. Am J Pathol 152:879–884

    PubMed  CAS  Google Scholar 

  4. Beach TG, Adler CH, Sue LI, Peirce JB, Bachalakuri J, Dalsing-Hernandez JE, Lue LF, Caviness JN, Connor DJ, Sabbagh MN, Walker DG (2008) Reduced striatal tyrosine hydroxylase in incidental Lewy body disease. Acta Neuropathol 115:445–451. doi:10.1007/s00401-007-0313-7

    Article  PubMed  CAS  Google Scholar 

  5. Beach TG, Sue LI, Walker DG, Roher AE, Lue L, Vedders L, Connor DJ, Sabbagh MN, Rogers J (2008) The Sun Health Research Institute Brain Donation Program: description and experience, 1987–2007. Cell Tissue Bank 9:229–245. doi:10.1007/s10561-008-9067-2

    Article  PubMed  Google Scholar 

  6. Beach TG, White CL, Hamilton RL, Duda JE, Iwatsubo T, Dickson DW, Roncaroli F, Buttini M, Hladik CL, Sue LI, Noorigian JV, Adler CH (2008) Evaluation of alpha-synuclein immunohistochemical methods used by invited experts. Acta Neuropathol 116:277–288. doi:10.1007/s00401-008-0409-8

    Article  PubMed  CAS  Google Scholar 

  7. Beach TG, White CLIII, Hladik CL, Sabbagh MN, Connor DJ, Shill HA, Sue LI, Sasse J, Bachalakuri J, Henry-Watson J, Akiyama H, Adler CH (2009) Olfactory bulb alpha-LTS has high specificity and sensitivity for Lewy body disorders. Acta Neuropathol 117:169–174. doi:10.1007/s00401-008-0450-7

    Article  PubMed  CAS  Google Scholar 

  8. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations. J Neurol Sci 20:415–455. doi:10.1016/0022-510X(73)90175-5

    Article  PubMed  CAS  Google Scholar 

  9. Bloch A, Probst A, Bissig H, Adams H, Tolnay M (2006) Alpha-synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. Neuropathol Appl Neurobiol 32:284–295. doi:10.1111/j.1365-2990.2006.00727.x

    Article  PubMed  CAS  Google Scholar 

  10. Braak H, Del Tredici K (2008) Invited article: nervous system pathology in sporadic Parkinson disease. Neurology 70:1916–1925. doi:10.1212/01.wnl.0000312279.49272.9f

    Article  PubMed  Google Scholar 

  11. Braak H, Braak E, Yilmazer D, de Vos RA, Jansen EN, Bohl J, Jellinger K (1994) Amygdala pathology in Parkinson’s disease. Acta Neuropathol 88:493–500. doi:10.1007/BF00296485

    Article  PubMed  CAS  Google Scholar 

  12. Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rub U (2002) Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson’s disease (preclinical and clinical stages). J Neurol 249(Suppl 3):III/1–III/5

    Google Scholar 

  13. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211. doi:10.1016/S0197-4580(02)00065-9

    Article  PubMed  Google Scholar 

  14. Braak H, Rub U, Gai WP, Del TK (2003) Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 110:517–536. doi:10.1007/s00702-002-0808-2

    Article  PubMed  CAS  Google Scholar 

  15. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K (2004) Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res 318:121–134. doi:10.1007/s00441-004-0956-9

    Article  PubMed  Google Scholar 

  16. Braak H, Bohl JR, Muller CM, Rub U, de Vos RA, Del Tredici K (2006) Stanley Fahn Lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson’s disease reconsidered. Mov Disord 21:2042–2051. doi:10.1002/mds.21065

    Article  PubMed  Google Scholar 

  17. Braak H, de Vos RA, Bohl J, Del Tredici K (2006) Gastric alpha-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology. Neurosci Lett 396:67–72. doi:10.1016/j.neulet.2005.11.012

    Article  PubMed  CAS  Google Scholar 

  18. Burke RE, Dauer WT, Vonsattel JP (2008) A critical evaluation of the Braak staging scheme for Parkinson’s disease. Ann Neurol 64:485–491. doi:10.1002/ana.21541

    Article  PubMed  Google Scholar 

  19. Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease (1997) The National Institute on Aging, and Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer’s disease. Neurobiol Aging 18:S1–S2

    Article  Google Scholar 

  20. Croisier E, Mres DE, Deprez M, Goldring K, Dexter DT, Pearce RK, Graeber MB, Roncaroli F (2006) Comparative study of commercially available anti-alpha-synuclein antibodies. Neuropathol Appl Neurobiol 32:351–356. doi:10.1111/j.1365-2990.2006.00722.x

    Article  PubMed  CAS  Google Scholar 

  21. Daniel SE, Hawkes CH (1992) Preliminary diagnosis of Parkinson’s disease by olfactory bulb pathology. Lancet 340:186. doi:10.1016/0140-6736(92)93275-R

    Article  PubMed  CAS  Google Scholar 

  22. Del Tredici K, Rub U, de Vos RA, Bohl JR, Braak H (2002) Where does Parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol 61:413–426

    PubMed  Google Scholar 

  23. Delledonne A, Klos KJ, Fujishiro H, Ahmed Z, Parisi JE, Josephs KA, Frigerio R, Burnett M, Wszolek ZK, Uitti RJ, Ahlskog JE, Dickson DW (2008) Incidental Lewy body disease and preclinical Parkinson disease. Arch Neurol 65:1074–1080. doi:10.1001/archneur.65.8.1074

    Article  PubMed  Google Scholar 

  24. den Hartog Jager WA, Bethlem J (1960) The distribution of Lewy bodies in the central and autonomic nervous systems in idiopathic paralysis agitans. J Neurol Neurosurg Psychiatry 23:283–290. doi:10.1136/jnnp.23.4.283

  25. Dickson DW, Fujishiro H, DelleDonne A, Menke J, Ahmed Z, Klos KJ, Josephs KA, Frigerio R, Burnett M, Parisi JE, Ahlskog JE (2008) Evidence that incidental Lewy body disease is pre-symptomatic Parkinson’s disease. Acta Neuropathol 115:437–444. doi:10.1007/s00401-008-0345-7

    Article  PubMed  Google Scholar 

  26. Doty RL, Deems DA, Stellar S (1988) Olfactory dysfunction in Parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 38:1237–1244

    PubMed  CAS  Google Scholar 

  27. Duda JE (2004) Pathology and neurotransmitter abnormalities of dementia with Lewy bodies. Dement Geriatr Cogn Disord 17(Suppl 1):3–14. doi:10.1159/000074677

    Article  PubMed  CAS  Google Scholar 

  28. Duda JE, Shah U, Arnold SE, Lee VM, Trojanowski JQ (1999) The expression of alpha-, beta-, and gamma-synucleins in olfactory mucosa from patients with and without neurodegenerative diseases. Exp Neurol 160:515–522. doi:10.1006/exnr.1999.7228

    Article  PubMed  CAS  Google Scholar 

  29. Duda JE, Giasson BI, Chen Q, Gur TL, Hurtig HI, Stern MB, Gollomp SM, Ischiropoulos H, Lee VM, Trojanowski JQ (2000) Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. Am J Pathol 157:1439–1445

    PubMed  CAS  Google Scholar 

  30. Duda JE, Giasson BI, Mabon ME, Lee VM, Trojanowski JQ (2002) Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann Neurol 52:205–210. doi:10.1002/ana.10279

    Article  PubMed  CAS  Google Scholar 

  31. Duda JE, Giasson BI, Mabon ME, Miller DC, Golbe LI, Lee VM, Trojanowski JQ (2002) Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred. Acta Neuropathol 104:7–11. doi:10.1007/s00401-002-0563-3

    Article  PubMed  CAS  Google Scholar 

  32. Ellis RJ, Jan K, Kawas C, Koller WC, Lyons KE, Jeste DV, Hansen LA, Thal LJ (1998) Diagnostic validity of the dementia questionnaire for Alzheimer disease. Arch Neurol 55:360–365. doi:10.1001/archneur.55.3.360

    Article  PubMed  CAS  Google Scholar 

  33. Fearnley JM, Lees AJ (1991) Ageing and Parkinson’s disease: SN regional selectivity. Brain 114(Pt 5):2283–2301. doi:10.1093/brain/114.5.2283

    Article  PubMed  Google Scholar 

  34. Fujimi K, Sasaki K, Noda K, Wakisaka Y, Tanizaki Y, Matsui Y, Sekita A, Iida M, Kiyohara Y, Kanba S, Iwaki T (2008) Clinicopathological outline of dementia with Lewy bodies applying the revised criteria: the Hisayama study. Brain Pathol 18:317–325. doi:10.1111/j.1750-3639.2008.00169.x

    Article  PubMed  Google Scholar 

  35. Fujishiro H, Tsuboi Y, Lin WL, Uchikado H, Dickson DW (2008) Co-localization of tau and alpha-synuclein in the olfactory bulb in Alzheimer’s disease with amygdala Lewy bodies. Acta Neuropathol 116:17–24. doi:10.1007/s00401-008-0383-1

    Article  PubMed  CAS  Google Scholar 

  36. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T (2002) Alpha-Synuclein is phosphorylated in LTS lesions. Nat Cell Biol 4:160–164. doi:10.1038/ncb841

    Article  PubMed  CAS  Google Scholar 

  37. Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson disease. Arch Neurol 56:33–39. doi:10.1001/archneur.56.1.33

    Article  PubMed  CAS  Google Scholar 

  38. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in LTS lesions. Science 290:985–989. doi:10.1126/science.290.5493.985

    Article  PubMed  CAS  Google Scholar 

  39. Giasson BI, Duda JE, Forman MS, Lee VM, Trojanowski JQ (2001) Prominent perikaryal expression of alpha- and beta-synuclein in neurons of dorsal root ganglion and in medullary neurons. Exp Neurol 172:354–362. doi:10.1006/exnr.2001.7805

    Article  PubMed  CAS  Google Scholar 

  40. Hamilton RL (2000) Lewy bodies in Alzheimer’s disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol 10:378–384

    PubMed  CAS  Google Scholar 

  41. Hansen L, Salmon D, Galasko D, Masliah E, Katzman R, DeTeresa R, Thal L, Pay MM, Hofstetter R, Klauber M (1990) The Lewy body variant of Alzheimer’s disease: a clinical and pathologic entity. Neurology 40:1–8

    PubMed  CAS  Google Scholar 

  42. Hawkes C (2006) Olfaction in neurodegenerative disorder. Adv Otorhinolaryngol 63:133–151

    PubMed  Google Scholar 

  43. Hawkes CH, Del Tredici K, Braak H (2007) Parkinson’s disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol 33:599–614. doi:10.1111/j.1365-2990.2007.00874.x

    Article  PubMed  CAS  Google Scholar 

  44. Hishikawa N, Hashizume Y, Yoshida M, Sobue G (2003) Clinical and neuropathological correlates of Lewy body disease. Acta Neuropathol 105:341–350

    PubMed  Google Scholar 

  45. Hixson JE, Vernier DT (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 31:545–548

    PubMed  CAS  Google Scholar 

  46. Hladik CL, White CL (2003) Comparison of digestive enzyme and formic acid pretreatment for optimal immunohistochemical demonstration of alpha-synuclein-immunoreactive cerebral cortical Lewy neurites. J Neuropathol Exp Neurol 62:554

    Google Scholar 

  47. Holdorff B (2002) Friedrich Heinrich Lewy (1885–1950) and his work. J Hist Neurosci 11:19–28. doi:10.1076/jhin.11.1.19.9106

    Article  PubMed  Google Scholar 

  48. Hubbard PS, Esiri MM, Reading M, McShane R, Nagy Z (2007) Alpha-synuclein pathology in the olfactory pathways of dementia patients. J Anat 211:117–124. doi:10.1111/j.1469-7580.2007.00748.x

    Article  PubMed  Google Scholar 

  49. Iseki E, Marui W, Kosaka K, Akiyama H, Ueda K, Iwatsubo T (1998) Degenerative terminals of the perforant pathway are human alpha-synuclein-immunoreactive in the hippocampus of patients with diffuse Lewy body disease. Neurosci Lett 258:81–84. doi:10.1016/S0304-3940(98)00856-8

    Article  PubMed  CAS  Google Scholar 

  50. Jellinger KA (2004) Lewy body-related alpha-LTS in the aged human brain. J Neural Transm 111:1219–1235. doi:10.1007/s00702-004-0138-7

    Article  PubMed  CAS  Google Scholar 

  51. Jellinger KA (2008) A critical reappraisal of current staging of Lewy-related pathology in human brain. Acta Neuropathol 116:1–16. doi:10.1007/s00401-008-0406-y

    Article  PubMed  CAS  Google Scholar 

  52. Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK (2008) The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson’s disease: a critical analysis of alpha-synuclein staging. Neuropathol Appl Neurobiol 34:284–295. doi:10.1111/j.1365-2990.2007.00923.x

    Article  PubMed  CAS  Google Scholar 

  53. Katzenschlager R, Lees AJ (2004) Olfaction and Parkinson’s syndromes: its role in differential diagnosis. Curr Opin Neurol 17:417–423. doi:10.1097/01.wco.0000137531.76491.c2

    Article  PubMed  Google Scholar 

  54. Klos KJ, Ahlskog JE, Josephs KA, Apaydin H, Parisi JE, Boeve BF, DeLucia MW, Dickson DW (2006) Alpha-synuclein pathology in the spinal cords of neurologically asymptomatic aged individuals. Neurology 66:1100–1102. doi:10.1212/01.wnl.0000204179.88955.fa

    Article  PubMed  CAS  Google Scholar 

  55. Kosaka K (2007) Dementia with Lewy bodies–from its finding to the present, including the CDLB guideline-revised. Rinsho Shinkeigaku 47:703–707

    Google Scholar 

  56. Kranick SM, Duda JE (2008) Olfactory dysfunction in Parkinson’s disease. Neurosignals 16:35–40. doi:10.1159/000109757

    Article  PubMed  CAS  Google Scholar 

  57. Kuusisto E, Parkkinen L, Alafuzoff I (2003) Morphogenesis of Lewy bodies: dissimilar incorporation of alpha-synuclein, ubiquitin, and p62. J Neuropathol Exp Neurol 62:1241–1253

    PubMed  CAS  Google Scholar 

  58. Lerner A, Bagic A (2008) Olfactory pathogenesis of idiopathic Parkinson disease revisited. Mov Disord 23:1076–1084. doi:10.1002/mds.22066

    Article  PubMed  Google Scholar 

  59. Leverenz J, Hamilton R, Tsuang DW, Schantz A, Vavrek D, Kukull W, Lopez O, Galasko D, Masliah E, Kaye J, Nixon R, Clark C, Trojanowsk JQ, Montine TJ (2008) Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient. Brain Pathol 1:1–2

    Google Scholar 

  60. Leverenz JB, Hamilton R, Tsuang DW, Schantz A, Vavrek D, Larson EB, Kukull WA, Lopez O, Galasko D, Masliah E, Kaye J, Woltjer R, Clark C, Trojanowski JQ, Montine TJ (2008) Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient. Brain Pathol 18:220–224. doi:10.1111/j.1750-3639.2007.00117.x

    Article  PubMed  Google Scholar 

  61. Lewy FH (1912) Paralysis agitans 1. Pathologisch Anatomie. In: Handbuch der Neurologie III. Springer, Berlin, pp 920–933

  62. Linazasoro G (2007) Classical Parkinson disease versus Parkinson complex–reflections against staging and in favour of heterogeneity. Eur J Neurol 14:721–728. doi:10.1111/j.1468-1331.2007.01853.x

    Article  PubMed  CAS  Google Scholar 

  63. Lippa CF, Smith TW, Swearer JM (1994) Alzheimer’s disease and Lewy body disease: a comparative clinicopathological study. Ann Neurol 35:81–88. doi:10.1002/ana.410350113

    Article  PubMed  CAS  Google Scholar 

  64. Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, Boeve BF, Brooks DJ, Dickson DW, Dubois B, Emre M, Fahn S, Farmer JM, Galasko D, Galvin JE, Goetz CG, Growdon JH, Gwinn-Hardy KA, Hardy J, Heutink P, Iwatsubo T, Kosaka K, Lee VM, Masliah E, McKeith IG, Nussbaum RL, Olanow CW, Ravina BM, Singleton AB, Tanner CM, Trojanowski JQ, Wszolek ZK (2007) DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 68:812–819. doi:10.1212/01.wnl.0000256715.13907.d3

    Article  PubMed  CAS  Google Scholar 

  65. Marui W, Iseki E, Nakai T, Miura S, Kato M, Ueda K, Kosaka K (2002) Progression and staging of Lewy pathology in brains from patients with dementia with Lewy bodies. J Neurol Sci 195:153–159. doi:10.1016/S0022-510X(02)00006-0

    Article  PubMed  Google Scholar 

  66. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47:1113–1124

    PubMed  CAS  Google Scholar 

  67. McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del ST, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65:1863–1872. doi:10.1212/01.wnl.0000187889.17253.b1

    Article  PubMed  CAS  Google Scholar 

  68. McKinnon JH, Demaerschalk BM, Caviness JN, Wellik KE, Adler CH, Wingerchuk DM (2007) Sniffing out Parkinson disease: can olfactory testing differentiate Parkinsonian disorders? Neurologist 13:382–385. doi:10.1097/NRL.0b013e31815a351a

    Article  PubMed  Google Scholar 

  69. Minguez-Castellanos A, Chamorro CE, Escamilla-Sevilla F, Ortega-Moreno A, Rebollo AC, Gomez-Rio M, Concha A, Munoz DG (2007) Do alpha-synuclein aggregates in autonomic plexuses predate Lewy body disorders? A cohort study. Neurology 68:2012–2018. doi:10.1212/01.wnl.0000264429.59379.d9

    Article  PubMed  CAS  Google Scholar 

  70. Müller CM, de Vos RA, Maurage CA, Thal DR, Tolnay M, Braak H (2005) Staging of sporadic Parkinson disease-related alpha-synuclein pathology: inter- and intra-rater reliability. J Neuropathol Exp Neurol 64:623–628

    PubMed  Google Scholar 

  71. Obi K, Akiyama H, Kondo H, Shimomura Y, Hasegawa M, Iwatsubo T, Mizuno Y, Mochizuki H (2008) Relationship of phosphorylated alpha-synuclein and tau accumulation to Abeta deposition in the cerebral cortex of dementia with Lewy bodies. Exp Neurol 210:409–420. doi:10.1016/j.expneurol.2007.11.019

    Article  PubMed  CAS  Google Scholar 

  72. Orimo S, Oka T, Miura H, Tsuchiya K, Mori F, Wakabayashi K, Nagao T, Yokochi M (2002) Sympathetic cardiac denervation in Parkinson’s disease and pure autonomic failure but not in multiple system atrophy. J Neurol Neurosurg Psychiatry 73:776–777. doi:10.1136/jnnp.73.6.776

    Article  PubMed  CAS  Google Scholar 

  73. Parkinson JD (1817) The shaking palsy. Sherwood, Neely and Jones, London

    Google Scholar 

  74. Parkinson JD (1955) An essay on the shaking palsy. In: Critchley M, Parkinson J (eds) Mcmillan, London

  75. Parkkinen L, Soininen H, Alafuzoff I (2003) Regional distribution of alpha-synuclein pathology in unimpaired aging and Alzheimer disease. J Neuropathol Exp Neurol 62:363–367

    PubMed  CAS  Google Scholar 

  76. Parkkinen L, Pirttila T, Alafuzoff I (2008) Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol 115:399–407. doi:10.1007/s00401-008-0346-6

    Article  PubMed  Google Scholar 

  77. Pearce RK, Hawkes CH, Daniel SE (1995) The anterior olfactory nucleus in Parkinson’s disease. Mov Disord 10:283–287. doi:10.1002/mds.870100309

    Article  PubMed  CAS  Google Scholar 

  78. Perry RH, Irving D, Blessed G, Fairbairn A, Perry EK (1990) Senile dementia of Lewy body type: a clinically and neuropathologically distinct form of Lewy body dementia in the elderly. J Neurol Sci 95:119–139. doi:10.1016/0022-510X(90)90236-G

    Article  PubMed  CAS  Google Scholar 

  79. Ross GW, Petrovitch H, Abbott RD, Nelson J, Markesbery W, Davis D, Hardman J, Launer L, Masaki K, Tanner CM, White LR (2004) Parkinsonian signs and SN neuron density in descendents elders without PD. Ann Neurol 56:532–539. doi:10.1002/ana.20226

    Article  PubMed  Google Scholar 

  80. Saito Y, Kawashima A, Ruberu NN, Fujiwara H, Koyama S, Sawabe M, Arai T, Nagura H, Yamanouchi H, Hasegawa M, Iwatsubo T, Murayama S (2003) Accumulation of phosphorylated alpha-synuclein in aging human brain. J Neuropathol Exp Neurol 62:644–654

    PubMed  CAS  Google Scholar 

  81. Saito Y, Ruberu NN, Sawabe M, Arai T, Kazama H, Hosoi T, Yamanouchi H, Murayama S (2004) Lewy body-related alpha-LTS in aging. J Neuropathol Exp Neurol 63:742–749

    PubMed  Google Scholar 

  82. Schiller F (2000) Fritz Lewy and his bodies. J Hist Neurosci 9:148–151. doi:10.1076/0964-704X(200008)9:2;1-Y;FT148

    Article  PubMed  CAS  Google Scholar 

  83. Sengoku R, Saito Y, Ikemura M, Hatsuta H, Sakiyama Y, Kanemaru K, Arai T, Sawabe M, Tanaka N, Mochizuki H, Inoue K, Murayama S (2008) Incidence and extent of Lewy body-related alpha-LTS in aging human olfactory bulb. J Neuropathol Exp Neurol 67:1072–1083. doi:10.1097/NEN.0b013e31818b4126

    Article  PubMed  Google Scholar 

  84. Tsuang DW, Riekse RG, Purganan KM, David AC, Montine TJ, Schellenberg GD, Steinbart EJ, Petrie EC, Bird TD (2006) Lewy body pathology in late-onset familial Alzheimer’s disease: a clinicopathological case series. J Alzheimers Dis 9:235–242

    PubMed  CAS  Google Scholar 

  85. Uchikado H, Lin WL, DeLucia MW, Dickson DW (2006) Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-LTS. J Neuropathol Exp Neurol 65:685–697. doi:10.1097/01.jnen.0000225908.90052.07

    Article  PubMed  CAS  Google Scholar 

  86. Wakabayashi K, Takahashi H, Takeda S, Ohama E, Ikuta F (1988) Parkinson’s disease: the presence of Lewy bodies in Auerbach’s and Meissner’s plexuses. Acta Neuropathol 76:217–221. doi:10.1007/BF00687767

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This research is supported by grants to the Sun Health Research Institute Brain Donation Program and the Arizona Parkinson’s Disease Consortium by the Michael J. Fox Foundation for Parkinson’s Research (The Prescott Family Initiative), the Arizona Biomedical Research Commission (contracts 4001, 0011 and 05-901) and the National Institute on Aging (P30 AG19610).

Author information

Authors and Affiliations

  1. Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, AZ, 85351, USA

    Thomas G. Beach, LihFen Lue, Lucia I. Sue, Jyothi Bachalakuri, Jonette Henry-Watson, Jeanne Sasse, Sarah Boyer, Scophil Shirohi, Reed Brooks, Holly A. Shill, Donald J. Connor, Marwan N. Sabbagh & Douglas G. Walker

  2. Mayo Clinic, Scottsdale, AZ, USA

    Charles H. Adler & John Caviness

  3. Barrow Neurological Institute, Phoenix, AZ, USA

    Jennifer Eschbacher

  4. University of Texas Southwestern Medical Center, Dallas, TX, USA

    Charles L. White III

  5. Tokyo Institute of Psychiatry, Tokyo, Japan

    Haru Akiyama

Authors
  1. Thomas G. Beach
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charles H. Adler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. LihFen Lue
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lucia I. Sue
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jyothi Bachalakuri
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jonette Henry-Watson
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jeanne Sasse
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Sarah Boyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Scophil Shirohi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Reed Brooks
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jennifer Eschbacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Charles L. White III
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Haru Akiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. John Caviness
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Holly A. Shill
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Donald J. Connor
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Marwan N. Sabbagh
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Douglas G. Walker
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

the Arizona Parkinson’s Disease Consortium

Corresponding author

Correspondence to Thomas G. Beach.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Beach, T.G., Adler, C.H., Lue, L. et al. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol 117, 613–634 (2009). https://doi.org/10.1007/s00401-009-0538-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00401-009-0538-8

Keywords

pFad - Phonifier reborn

Pfad - The Proxy pFad of © 2024 Garber Painting. All rights reserved.

Note: This service is not intended for secure transactions such as banking, social media, email, or purchasing. Use at your own risk. We assume no liability whatsoever for broken pages.


Alternative Proxies:

Alternative Proxy

pFad Proxy

pFad v3 Proxy

pFad v4 Proxy